Doctors and nurses in Houston’s Memorial Hermann Hospital scramble among hospital beds, making split-second decisions on treatment based on experience and a half-dozen blinking screens flashing different vital signs.
“There are a lot of data sets—plus, blood on the floor,” says... Read more »
Aside from rent increases, few effects of the economic boom lifting up the San Francisco Bay Area (or afflicting it, depending on your point of view) have drawn more ire and resentment lately than the private buses.
These big, faceless, Wi-Fi-equipped... Read more »
When is a page view not a real page view?
That is one of the questions MdotLabs offers to help Web companies answer through its software.
Much of the revenue in digital publishing and online ads rides on audience flow. So... Read more »
In the seven years since companies including Genentech/Roche and Regeneron launched new drugs to slow vision loss from an eye disorder called “wet” age-related macular degeneration, the market for those drugs has risen to an estimated $4 billion.
But that substantial... Read more »
Four years ago, Exact Sciences was roadkill. The company, based in greater Boston at the time, had been experimenting with molecular diagnostic technologies for more than a dozen years. It had a stellar scientific pedigree from founder Stanley Lapidus. But it... Read more »
In a move to democratize its data visualization technology and expand its market, Solana Beach, CA-based Roambi says today it is launching a new iPad app intended to bring the power of its Roambi Flow publishing platform to the Internet... Read more »
Fundraising, layoff, and acquisition news from around the IT software and robotics sectors in the past few days:
—Infinio, a Cambridge, MA-based IT software developer, says it has raised a $12 million Series B investment. The money comes... Read more »
George Church created the Personal Genome Project, a big plan to sequence more than 100,000 human genomes in the U.S. Now the database he’s been using to store all that information has become the basis for a new startup.
Boston-based Curoverse... Read more »
[Updated: 7:40 am PT 12/18/13] Seattle-based Acucela is looking to raise as much as $125 million in an initial public offering to support its development of treatments against eye diseases.
Acucela today filed its IPO prospectus with the Securities... Read more »